Pharmacokinetics & Drug Delivery | Immunopharmacology & Hematologic Pharmacology | Molecular Pharmacology | Bleeding & Coagulation Disorders
Functional characterization of recombinant factor IX albumin fusion protein
Carsten Horn*, Burkhard Watzka, Hubert J Metzner, Thomas Weimer, Gerhard Dickneite, Stefan Schulte
*Corresponding author: Carsten Horn
CSL Behring GmbH, Marburg, Germany
F1000Posters 2012, 3: 372 (poster) [English]
Poster [672.95 KB]
Presented at
56. Gesellschaft für Thrombose und Hämostaseforschung (German Society of Thrombosis and Haemostasis) 2012,
1 - 4 Feb 2012, P2-45
Improvement of the pharmacokinetic properties of factor IX (FIX) has the potential to increase convenience and compliance of the treatment of severe hemophilia B by reducing the dosing frequency. A concept for half-life increase of FIX was developed based on recombinant fusion protein technology linking recombinant coagulation factor IX and albumin (rIX-FP) via a cleavable linker.
The aim of this study was the functional characterization and comparison of rIX-FP to two commercially available FIX products – a recombinant ( r ) FIX (BeneFIX®) and a plasma-derived (pd) concentrate (Mononine®).
The ability of activated FIX (FIXa) to activate factor X (FX), as well as the inhibition of FIXa by antithrombin (AT), was investigated to assess structural functionality of FIXa. AT was able to inhibit FIXa activity completely in a concentration-dependent manner. The half-maximal inhibition was comparable for activated rIX-FP and FIX products, respectively. In a comparable, time-dependent manner, FXa was formed in presence of activated factor VIII (FVIIIa) by activated rIX-FP and pd or rFIX, respectively. Taken together, comparing activated rIX-FP and FIX products (BeneFIX® and Mononine®), a high degree of comparability was found in the assays applied.
All authors are employees of CSL Behring.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
